Navigation Links
Experienced Drug Development and Partnering CEO Takes the Helm at Tolera
Date:12/3/2013

KALAMAZOO, Mich., Dec. 3, 2013 /PRNewswire/ -- Tolera Therapeutics, Inc., a privately-held, immune therapy company developing a novel T-cell targeted therapeutic platform, announced today that it has appointed Ashleigh Palmer as President, CEO and Board Director.

Tolera's Chairman, Suzette Dutch, Managing Partner of Triathlon Medical Ventures, said, "Ashleigh has an ideal track record in developing, partnering and commercializing advanced-stage biopharma assets and pioneering therapeutic platforms.  The board is delighted with Ashleigh's appointment and is committed to supporting him as he evaluates and recommends Tolera's best path forward."

While taking the lead at Tolera, Mr. Palmer will continue as President of Creative BioVentures™ Corp., a strategic advisory serving the biopharma industry.  Since founding Creative BioVentures in 2002, Palmer has undertaken several challenging development-stage and turnaround assignments, including CEO and Chairman of Restoragen, Inc.; CEO of Canfite Biopharma, Ltd.; and CEO of Unigene Laboratories, Inc.

Previously, Palmer was Vice President of Business Development at Ohmeda, Inc., where he played an instrumental role in its $1.2 billion sale to a Baxter-led consortium by spinning out Ohmeda's inhaled nitric oxide assets to found INO Therapeutics, Inc.  Under Palmer's leadership, as founding President and CEO, INO Therapeutics developed and commercialized the world's first selective pulmonary vasodilator, INOmax®, establishing an orphan drug franchise subsequently acquired by Ikaria for $670 million.

Earlier in his career, Palmer held positions of increasing responsibility in sales and marketing management at Reckitt Benckiser, PLC and SSL International, PLC.  He received his MBA from the University of Bradford, England and his BSc. honors in Biochemistry and Applied Molecular Biology from the University of Manchester, England.

"Having completed a successful Phase 2 renal transplantation study for its lead product candidate, TOL101, Tolera is now poised to carefully consider its strategic options, evaluate the needs of prospective partners, and advance this novel therapeutic approach towards a market that appears ripe for the entry of an advantageous induction agent," commented Palmer.  "Tolera also has a significant opportunity to advance its broader T-cell targeting therapeutic platform, especially with respect to autoimmune disease and cancer.  Effective partnering will be the key to this endeavor."

About Tolera Therapeutics   
Tolera Therapeutics is a biotechnology company focused on developing and commercializing a highly specific, T-cell antagonist, monoclonal antibody technology (anti-TCR) with application potential across a broad spectrum of T-cell mediated diseases, such as transplant rejection, autoimmune disease and cancer.  Its lead product candidate, TOL101, has to date successfully completed clinical testing through Ph2 and is ready to commence advanced stage clinical testing having received approval of a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial comparing TOL101 to Thymoglobulin.  Primary investors in the company include Triathlon Medical Venture Partners, Hopen Life Science Ventures, the SWMF Life Science Fund, and the Michigan Economic Development Corporation.  Additional information concerning the company and its technology can be found on its website www.tolera.com.

Media Contact: 
Jason Rando  
Tiberend Strategic Advisors, Inc. 
212.375.2665 
jrando@tiberend.com  


'/>"/>
SOURCE Tolera Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. ERT Acquires invivodata to Establish the Industrys Most Experienced Provider of Clinical Outcome Assessment Solutions
3. RxAlly Announces Addition Of Experienced Corporate Counsel Tom OGrady To The Companys Leadership Team
4. Safe in Common Offers Experienced Advice for U.K.s Review of Needlestick Safety Regulations
5. Survey of Oncologists Reveals 98.9% of Physicians Experienced Cancer Drug Shortages in Last 12 Months
6. Experienced Surgeon Vs. FDA-Approved Robot
7. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
8. Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
9. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
10. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
11. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... July 31, 2017 7D Surgical, developer of ground ... purchased the 7D Surgical System to support its strategic sales ... D.C. and Virginia.  7D Surgical has entered into ... of the premier medical facilities within those markets. ... ...
(Date:7/27/2017)... Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results ... reported second quarter net sales of $1.954 billion, an ... an increase of 2.1% on a constant currency basis.  ... LDR Holding Corporation acquisition, second quarter 2017 revenues decreased ... on a constant currency basis. ...
(Date:7/26/2017)... a leading medical aesthetic clinic in Singapore ... conditions from the inside. The natural process of aging ... becomes more transparent due to the thinning of the epidermis. Over the ... sun contributes to aging skin, causing age spots and other types ... ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has released a new publication this ... of the Savior whom the world calls “Mother Mary”. Yisrayl says when compared to what ... historical woman. , “The world bows, kisses the feet of, cries out to and ...
(Date:8/18/2017)... ... August 18, 2017 , ... 800response, the leading ... solutions, announced today the launch of a redesigned corporate website, 800response.com . ... fully responsive design, and an enhanced search directory for businesses and advertising agencies ...
(Date:8/18/2017)... ... ... “Three Narrow Roads”: a vivid and provocative look into the narrow path toward ... Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a global prayer ministry ... program geared towards youth. , King shares, “When I take time to think about ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch ... new products are an affordable, yet effective alternative to expensive plastic surgery or ...
(Date:8/18/2017)... ... ... “Steve the Snake”: an entertaining and moral-based short story about an unkind snake ... Flash Haskins Jr., a husband, father and grandfather who served as a U.S. Marine, ... short stories for children and teens. My goal is to teach kids to use ...
Breaking Medicine News(10 mins):